News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Subscribe To Our Newsletter & Stay Updated
